Opinion|Videos|November 26, 2024
Implications of IPF Survival Data for Clinical Practice and Early Intervention
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the data from the IPF-PRO Registry highlights the critical relationship between early diagnosis and prognosis in IPF, revealing that FVC percent predicted, oxygen use, BMI, and age are key indicators of long-term survival, underscoring the importance of early identification, and personalized treatment plans to improve patient outcomes.
Advertisement
Episodes in this series
- What are your key takeaways from this study, and how has the data enhanced our understanding of the relationship between early diagnosis and prognosis in patients with IPF?
Advertisement
Related to this article
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.
Older patients with obstructive sleep apnea (OSA) had more cardiometabolic disease and poorer reported sleep quality than younger patients.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
5 Things to Know About the One Big Beautiful Bill Act
3
New CHEST Guidelines Offer a Road Map for Bronchiectasis
4
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
5